Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Area of Science:

• Oncology
• Genetics
• Pediatric Medicine

Background:

• Rhabdomyosarcoma (RMS) is a rare, heterogeneous pediatric soft-tissue sarcoma.
• Fusion-positive RMS involves PAX3/PAX7-FOXO1 gene translocations, while fusion-negative RMS often shows RAS pathway activation.
• Metastatic disease is more common in fusion-positive RMS, and cure rates are low for high-risk groups, including adults.

Purpose of the Study:

• To outline current challenges in Rhabdomyosarcoma research.
• To identify implications for developing more effective therapies.
• To highlight critical areas for future research and collaboration.

Main Methods:

• This white paper reviews existing research and clinical challenges in Rhabdomyosarcoma.
• It discusses biological and clinical problems requiring further investigation.
• It proposes strategies to streamline therapeutic development.

Main Results:

• Urgent clinical issues include local control, systemic disease management, risk stratification, and understanding age-related differences.
• Biological challenges involve defining PAX-FOXO1 fusion protein functions, clarifying heterogeneity, elucidating origins, and characterizing the tumor microenvironment.
• Identifying rational combination therapies is crucial.

Conclusions:

• Improving access to fresh tumor tissue is critical for research.
• Alternative clinical trial designs are needed for efficient drug testing.
• Collaboration between academia and industry, alongside advocacy, is essential for advancing RMS therapies.